Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nasal salmon calcitonin in osteoporosis.

Literature DB >> 7953983

Nasal salmon calcitonin in osteoporosis.

K Overgaard, B J Riis.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1994 PMID： 7953983 DOI： 10.1007/BF00297178

Source DB: PubMed Journal: Calcif Tissue Int ISSN： 0171-967X Impact factor: 4.333

× No keyword cloud information.

35 in total

1. Nasal calcitonin for treatment of established osteoporosis.

Authors: K Overgaard; B J Riis; C Christiansen; J Pødenphant; J S Johansen
Journal: Clin Endocrinol (Oxf) Date: 1989-04 Impact factor: 3.478

2. Epidemiology of vertebral fractures in women.

Authors: L J Melton; S H Kan; M A Frye; H W Wahner; W M O'Fallon; B L Riggs
Journal: Am J Epidemiol Date: 1989-05 Impact factor: 4.897

3. Effect of different doses of nasal salmon calcitonin on bone mass.

Authors: G Thamsborg; T L Storm; R Sykulski; E Brinch; H K Nielsen; O H Sørensen
Journal: Calcif Tissue Int Date: 1991-05 Impact factor: 4.333

4. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors: B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal: N Engl J Med Date: 1990-03-22 Impact factor: 91.245

5. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis.

Authors: C Gennari; D Agnusdei; A Camporeale
Journal: Osteoporos Int Date: 1993 Impact factor: 4.507

6. Effect of salcatonin given intranasally on early postmenopausal bone loss.

Authors: K Overgaard; B J Riis; C Christiansen; M A Hansen
Journal: BMJ Date: 1989-08-19

7. Treatment of postmenopausal osteoporosis with transdermal estrogen.

Authors: E G Lufkin; H W Wahner; W M O'Fallon; S F Hodgson; M A Kotowicz; A W Lane; H L Judd; R H Caplan; B L Riggs
Journal: Ann Intern Med Date: 1992-07-01 Impact factor: 25.391

8. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.

Authors: J Y Reginster; D Denis; R Deroisy; M P Lecart; M De Longueville; B Zegels; N Sarlet; P Noirfalisse; P Franchimont
Journal: J Bone Miner Res Date: 1994-01 Impact factor: 6.741

Nasal salmon calcitonin in osteoporosis.

1. Nasal calcitonin for treatment of established osteoporosis.

2. Epidemiology of vertebral fractures in women.

3. Effect of different doses of nasal salmon calcitonin on bone mass.

4. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

5. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis.

6. Effect of salcatonin given intranasally on early postmenopausal bone loss.

7. Treatment of postmenopausal osteoporosis with transdermal estrogen.

8. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.

9. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease.

10. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Review 1. Advances in Controlled Drug Delivery for Treatment of Osteoporosis.

2. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

Review 3. Current and potential future drug treatments for osteoporosis.